Your browser doesn't support javascript.
loading
Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.
Yi, Yali; Cai, Jing; Xu, Peng; Xiong, Le; Lu, Zhiqin; Zeng, Zhimin; Liu, Anwen.
Afiliação
  • Yi Y; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi province, China.
  • Cai J; Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi province, China.
  • Xu P; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi province, China.
  • Xiong L; Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi province, China.
  • Lu Z; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi province, China.
  • Zeng Z; Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi province, China.
  • Liu A; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi province, China.
J Transl Med ; 20(1): 122, 2022 03 14.
Article em En | MEDLINE | ID: mdl-35287683

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article